JP2004051530A - Intestinal flora-improving agent and food or drink containing the same - Google Patents

Intestinal flora-improving agent and food or drink containing the same Download PDF

Info

Publication number
JP2004051530A
JP2004051530A JP2002210445A JP2002210445A JP2004051530A JP 2004051530 A JP2004051530 A JP 2004051530A JP 2002210445 A JP2002210445 A JP 2002210445A JP 2002210445 A JP2002210445 A JP 2002210445A JP 2004051530 A JP2004051530 A JP 2004051530A
Authority
JP
Japan
Prior art keywords
intestinal flora
improving agent
bacteria
lactic acid
heat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002210445A
Other languages
Japanese (ja)
Inventor
Tatsuhiko Suga
菅 辰彦
Wagon Takegawa
武川 和琴
Koei Yanagisawa
柳澤 昊永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combi Corp
Original Assignee
Combi Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combi Corp filed Critical Combi Corp
Priority to JP2002210445A priority Critical patent/JP2004051530A/en
Publication of JP2004051530A publication Critical patent/JP2004051530A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an intestinal flora-improving agent which has an excellent intestinal flora-improving action and does not deteriorate the effect, even when heated, and to provide a drink or food containing the same. <P>SOLUTION: This intestinal flora-improving agent is characterized by containing the thermally treated cells of one or more of lactobacillus, Bacillus bifidus, Bacillus natto and yeast. The thermally treated cells of the lactobacillus is especially preferably the thermally treated cells of Enterococcus faecalis. The intestinal flora-improving agent is preferably an agent prepared so that the thermally treated cells can be taken in an amount of ≥1×10<SP>10</SP>cells /day. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明の属する技術分野】
本発明は、乳酸菌等の加熱処理菌体を有効成分として含有し、加熱処理しても腸内菌叢改善効果を失うことのない腸内菌叢改善剤及びそれを含有する飲食品に関する。
【0002】
【従来の技術】
ヒトの腸内(特に大腸)には、多種多様な細菌(腸内細菌)が定住しており、腸内菌叢(腸内フローラ)と呼ばれる細菌群を形成している。腸内菌叢は、100種類以上、100兆個の腸内細菌から構成されていると言われており、ヒト(宿主)の健康と密接な関係があることが知られている。腸内細菌は、ヒトが消化できなかった食物残渣や消化管からの分泌物等を餌として増殖して便となって体外に排出され、便の固形分の3分の1から、多い時は2分の1位までが腸内細菌の菌体である。
【0003】
腸内菌叢を構成する細菌として、ビフィズス菌、バクテロイデス、ユウバクテリウム、クロストリジウム、大腸菌、乳酸桿菌、腸球菌等が知られている。腸内菌叢における細菌のバランスは相当の個人差はあってもその人自身のバランスは新生児の頃から成年に至るまで健康時ではほとんど変わらないと言われている。しかし、ストレス、過労、暴飲・暴食、偏食、気候・温度、薬、感染、加齢等の様々な要因によって、そのバランスが崩れ、ビフィズス菌等の有用菌が減少してウエルシュ菌や大腸菌等の有害菌が増えると、下痢、便秘、免疫力の低下による感染症、腸内腐敗産物の増加による発ガン等の様々な疾患の原因になることが指摘されている。
【0004】
乳酸菌やビフィズス菌等の有用菌は、乳酸や酢酸等の有機酸を産生してウエルシュ菌や大腸菌等の有害菌の増殖を抑制し、腸内菌叢を良好な状態に保つことが知られており、乳酸菌やビフィズス菌等の生菌を含む、生菌製剤、発酵乳、乳酸菌飲料、納豆等を積極的に摂取することにより、腸内菌叢のバランスが改善されることが分かっている。
【0005】
一般に、乳酸菌やビフィズス菌等を摂取して腸内菌叢のバランスを改善するためには、これらの菌を生きたまま腸に到達させて定着させる必要があると言われている(日本食品科学工学会誌、第48巻、第1号、p35〜43、2001年1月)。しかし、乳酸菌やビフィズス菌等は酸に弱く、生菌を摂取しても胃酸や胆汁酸等でそのほとんどが死んでしまうため、これらの菌を生きたまま腸に到達できるように、より高い耐酸性を有する菌株の選択やカプセル化等の様々な方法が行なわれている。
【0006】
また、元々腸内にいるビフィズス菌等を増やすことによって腸内菌叢を改善するために、食物繊維やビフィズス菌に選択的に資化される各種オリゴ糖(ビフィズス菌増殖因子)を配合した飲食品もあるが、腸内菌叢改善効果が期待できるような量の食物繊維や上記オリゴ糖を摂取した場合、おなかが張ったり、下痢を起こしたりすることがあった。
【0007】
【発明が解決しようとする課題】
上記のように乳酸菌やビフィズス菌等の摂取による腸内菌叢のバランス改善効果はこれらの生菌に由来するものであるとの認識が一般的であり、これまでに乳酸菌やビフィズス菌等の死菌体による腸内菌叢改善効果について研究されたことはなかった。また、同様の理由から腸内菌叢の改善を目的とする場合、乳酸菌やビフィズス菌等を添加した後にも加熱処理が必要とされるような飲食品に添加することは行なわれていない。
【0008】
したがって、本発明の目的は、優れた腸内菌叢改善作用を有し、加熱処理してもその効果が損われることのない腸内菌叢改善剤及びそれを含有する飲食品を提供することにある。
【0009】
【課題を解決するための手段】
本発明者らは、上記目的を達成するために鋭意研究した結果、意外にも乳酸菌等の加熱処理菌体を摂取することにより、ビフィズス菌の増殖が促進され、有害菌の増殖が抑制されて、腸内菌叢が改善されることを見出し、本発明を完成するに至った。
【0010】
すなわち、本発明の一つは、乳酸菌、ビフィズス菌、納豆菌及び酵母から選ばれた1種以上の加熱処理菌体を有効成分として含有することを特徴とする腸内菌叢改善剤である。
【0011】
本発明の腸内菌叢改善剤は、乳酸菌、ビフィズス菌、納豆菌及び酵母から選ばれた1種以上の加熱処理菌体を有効成分として含有することにより、理由は明確には分からないが、腸内のビフィズス菌の増殖を促進し、ウエルシュ菌等の有害菌の増殖を抑制して腸内菌叢を良好な状態に改善する効果を有する。その結果、糞便性状を良好にし、便秘症状を改善することができる。また、有効成分である乳酸菌等の加熱処理菌体は死菌体であるので、更に加熱処理を行なってもその腸内菌叢改善効果が損われることがない。したがって、加熱処理が必要な飲食品にも幅広く添加することができ、また、保存安定性が高く、飲食品や医薬品の原料として用いる場合の安全性も非常に高い。
【0012】
本発明の腸内菌叢改善剤は、乳酸菌の加熱処理菌体を有効成分として含有することが好ましい。また、前記乳酸菌が乳酸球菌(Enterococcus faecalis)であることが好ましい。これらの態様によれば、より高い腸内菌叢改善効果を有する腸内菌叢改善剤を得ることができる。
【0013】
更に、前記加熱処理菌体を1日当たり1×1010個以上摂取できるように調製されたものであることが好ましい。この態様によれば、充分な腸内菌叢改善効果を有する腸内菌叢改善剤を得ることができる。
【0014】
また、本発明のもう一つは、上記腸内菌叢改善剤を含有することを特徴とする飲食品である。
【0015】
本発明の飲食品は、乳酸菌等の加熱処理菌体を有効成分として含有する腸内菌叢改善剤を含有するので、摂取することにより優れた腸内菌叢改善効果が期待できる。該腸内菌叢改善剤は死菌体を有効成分とするので、加熱処理が必要な飲食品であっても腸内菌叢改善効果が損なわれることがなく、また、乳酸菌等による不要な発酵が起こることがないので、飲食品の保存安定性に影響を与えることもない。
【0016】
【発明の実施の形態】
本発明の腸内菌叢改善剤は、乳酸菌、ビフィズス菌、納豆菌及び酵母から選ばれた1種以上の加熱処理菌体を有効成分として含有するものである。
【0017】
乳酸菌としては、例えば、Enterococcus faecalisEnterococcus faeciumLactobacillus acidophilusLactobacillus caseiLactobacillus lactisStr eptococcus thermophilus等が挙げられる。
ビフィズス菌としては、例えば、Bifidobacterium LongumBifidobacterium breveBifidobacterium bifidum等が挙げられる。
納豆菌としては、例えば、Bacillus Natto等が挙げられる。
酵母としては、例えば、Saccharomyces cerevisiaeSaccharomyces Carlsbergensis等が挙げられる。
【0018】
本発明における加熱処理菌体とは、上記の菌を加熱殺菌して得られる死菌体であり、上記の菌を常法にしたがって培養して得られた培養物から、例えば、濾過、遠心分離等の方法により菌体を回収し、水洗後、水等に懸濁して80〜115℃、30分〜3秒間加熱処理した後、必要に応じて濃縮、乾燥することにより調製できる。
【0019】
本発明の腸内菌叢改善剤は、上記菌の中でも乳酸菌の加熱処理菌体を含有することが好ましく、特にEnterococcus faecalis(ATCC 19433、ATCC 14508、ATCC 23655、IFO 16803、IFO 16804等)の加熱処理菌体を含有することが好ましい。
【0020】
本発明の腸内菌叢改善剤は、上記菌の加熱処理菌体を1日当たり1×1010個以上、より好ましくは5×1011個以上、特に好ましくは1×1012個以上摂取できるように調製されていることが好ましい。該加熱処理菌体の1日当たりの摂取量が上記より少ないと、充分な腸内菌叢改善効果が期待できない。
【0021】
本発明の腸内菌叢改善剤は、上記の加熱処理菌体の他に、必要に応じて、賦形剤、甘味料、酸味料、ビタミン類、ミネラル類、オリゴ糖類、食物繊維等を添加して、粉末、顆粒、錠剤、カプセル剤、ペースト状又はゼリー状の飲料として調製することができる。
【0022】
また、本発明の腸内菌叢改善剤を、例えば、パン、うどんやラーメン等の各種麺類、納豆、ドリンク剤やゼリー飲料等の各種飲料、ゼリー、グミ、キャンディー、ビスケット、インスタントスープやインスタント味噌汁等の各種インスタント食品、レトルト食品、電子レンジ対応食品等の一般の飲食品に添加することもできる。上記各飲食品における腸内菌叢改善剤の添加量は、各飲食品中に上記加熱処理菌体が1×1010個以上、より好ましくは5×1011個以上、特に好ましくは1×1012個以上含有されるように添加することが好ましい。なお、添加方法は、特に制限はなく、各飲食品に用いられる他の原料と一緒に最初から添加することができる。
【0023】
本発明の腸内菌叢改善剤は、乳酸菌等の加熱処理菌体、すなわち死菌体を有効成分とするので、加熱処理(加熱殺菌、焼成、蒸煮等の菌体が死滅するような温度条件下での処理)が必要な飲食品に添加しても、腸内菌叢改善効果が損われることがない。
【0024】
【実施例】
以下、実施例を挙げて本発明を具体的に説明する。なお、以下の説明において、特に断りのない限り、「%」は「質量%」を表す。
【0025】
実施例
Enterococcus faecalis(ATCC 19433)をロゴサ培地で37℃、24時間培養した前培養液を、酵母エキス4%、ポリペプトン3%、乳糖10%を含む液体培地に0.1(v/v)%接種し、pHスタットを用いてpH6.8〜7.0に苛性ソーダ水溶液で調整しながら37℃、22〜24時間中和培養を行なった。
【0026】
培養終了後、連続遠心機で菌体を分離、回収した後、水を加えて元の液量まで希釈して再度連続遠心機で菌体を分離、回収した。この操作を合計4回繰り返して菌体を洗浄した。次いで、洗浄した菌体を適量の水に懸濁し、100℃、30分間殺菌した後、スプレードライヤーを用いて菌体を乾燥して加熱処理菌体粉末を調製した。
【0027】
得られた加熱処理菌体粉末を用いて、表1に示す組成で試験サンプル及びプラセーボ(それぞれ1g/包)を調製し、以下の方法により実験を行なった。なお、試験サンプルは、乳酸菌加熱処理菌体を1×1012個含むように調製した。
【0028】
【表1】

Figure 2004051530
【0029】
実験期間は4週間とし、ボランティア8名に、最初の1週間はプラセーボを1日1回1g/包を就寝前に服用してもらい、次の2週間は試験サンプルを同様に服用してもらい、最後の1週間はプラセーボを同様に服用してもらった。そして、0日目(実験前)、7日目(プラセーボ服用1週間目)、14日目(試験サンプル服用1週間目)、21日目(試験サンプル服用2週間目)、28日目(プラセーボ服用1週間目)にそれぞれ糞便を採取してもらい、糞便中の菌叢の変化を調べた。
【0030】
糞便中の菌叢の測定は、光岡知足の方法(感染症学会雑誌 45巻 第9号、406頁〜)に準じて行なった。すなわち、採取した糞便1gを乳鉢に取り、嫌気希釈液9mLを加えて均質化した後、嫌気希釈液を用いて10倍段階希釈した。この希釈液を、BL培地及びネオマイシンNagler寒天培地(NN培地)に塗布して、嫌気下、37℃で培養し、総菌数、バクテロイデス、ビフィズス菌、ウエルシュ菌の数を測定した。なお、上記嫌気希釈液は、蒸留水に、KHPOを4.5g、NaHPOを6.0g、L−システイン塩酸塩を0.5g、Tween 80を0.5g加え、全量を1000mLに調製したものである。また、総菌数は、BL培地に出現したコロニー数に希釈倍率を乗じて求めた。バクテロイデス及びビフィズス菌は、BL培地に出現したコロニーを釣菌し、グラム染色と検鏡により同定した。ウエルシュ菌は、NN培地を使用し、コロニー周囲のレシチナーゼ反応陽性のものをウエルシュ菌と判定した。そして、糞便1g中に含まれる総菌数、ビフィズス菌数及びウエルシュ菌数の変化を図1に示した。
【0031】
図1から、試験サンプル(乳酸菌加熱処理菌体)の服用期間に該当する実験期間14日目〜21日目において、ビフィズス菌数が有意に増加し、ウエルシュ菌数が有意に減少していることが分かる。なお、有意差の検定は、t−検定で行なった。
【0032】
また、総菌数に占めるビフィズス菌及びバクテロイデスの割合を表2に示した。
【0033】
【表2】
Figure 2004051530
【0034】
表2からも同様に、試験サンプルの服用期間に該当する実験期間14日目〜21日目において、総菌数に占めるビフィズス菌の割合が増加し、バクテロイデスの割合が減少していることが分かる。
【0035】
また、各被験者に実験期間中の排便状況についてアンケートしたところ、下痢等の症状は見られなかった。そして、普段から便秘気味の被験者を含むほとんどの被験者において、試験サンプルの服用期間に該当する実験期間中は、排便回数が増えると共に糞便性状も良好になり、便秘が改善される傾向にあった。
【0036】
以上の結果から、乳酸菌(Enterococcus fecalis)の加熱処理菌体を摂取することにより、腸内のビフィズス菌の増殖を促進し、バクテロイデスやウエルシュ菌等の有害菌の増殖を抑制して腸内菌叢を改善する効果があり、更に便秘改善効果もあることが示された。
【0037】
【発明の効果】
以上説明したように、本発明によれば、乳酸菌、ビフィズス菌、納豆菌及び酵母から選ばれた1種以上の加熱処理菌体を有効成分として含有させることにより、腸内のビフィズス菌の増殖を促進し、バクテロイデスやウエルシュ菌等の有害菌の増殖を抑制する効果を有する腸内菌叢改善剤を提供できる。この腸内菌叢改善剤を摂取することにより、腸内菌叢を良好な状態に改善することができ、また、糞便性状を良好にして、便秘等の症状を改善することができる。
【0038】
本発明の腸内菌叢改善剤は、死菌体を有効成分とするので、加熱処理が必要な飲食品にも幅広く添加することができ、様々な飲食品に腸内菌叢改善効果を付与できる。更に、飲食品に添加しても、乳酸菌等による不要な発酵が起こることがないので、飲食品の保存安定性に影響を与えることがなく、また、飲食品、医薬品の原料として用いる場合の安全性も非常に高い。
【図面の簡単な説明】
【図1】乳酸菌(Enterococcus fecalis)の加熱処理菌体の摂取による糞便中の菌叢の変化を示す図である。[0001]
BACKGROUND OF THE INVENTION
TECHNICAL FIELD The present invention relates to an intestinal flora improving agent that contains heat-treated cells such as lactic acid bacteria as an active ingredient and does not lose the intestinal flora improving effect even when heat-treated, and a food or drink containing the same.
[0002]
[Prior art]
A wide variety of bacteria (intestinal bacteria) have settled in the human intestine (particularly the large intestine), forming a group of bacteria called intestinal flora (intestinal flora). The intestinal flora is said to be composed of 100 types or more and 100 trillion intestinal bacteria, and is known to be closely related to human (host) health. Enterobacteria grow from food residues and digestive tract secretions that humans could not digest, and are excreted out of the body as stool. Up to half of the cells are enteric bacteria.
[0003]
Bifidobacteria, Bacteroides, Eubacterium, Clostridium, Escherichia coli, lactobacilli, enterococci and the like are known as bacteria constituting the intestinal flora. The balance of bacteria in the gut microbiota is said to be almost unchanged during health from the time of a newborn to adulthood, even though there are considerable individual differences. However, due to various factors such as stress, overwork, overdrinking / overeating, unbalanced eating, climate / temperature, medicine, infection, aging, etc., the balance is lost, and useful bacteria such as bifidobacteria are reduced, and welsh bacteria, E. coli, etc. It has been pointed out that an increase in harmful bacteria may cause various diseases such as diarrhea, constipation, infection due to decreased immunity, and carcinogenesis due to increased intestinal rot products.
[0004]
Useful bacteria such as lactic acid bacteria and bifidobacteria are known to produce organic acids such as lactic acid and acetic acid to suppress the growth of harmful bacteria such as Clostridium perfringens and Escherichia coli, and to keep the intestinal flora in a good state. In addition, it has been found that the intestinal flora balance is improved by actively ingesting viable bacterial preparations, fermented milk, lactic acid bacteria beverages, natto, etc., including viable bacteria such as lactic acid bacteria and bifidobacteria.
[0005]
In general, it is said that in order to improve the balance of intestinal flora by ingesting lactic acid bacteria, bifidobacteria, etc., it is necessary to allow these bacteria to reach the intestines while alive (Japanese Food Science) Journal of Engineering Society, Vol. 48, No. 1, p35-43, January 2001). However, lactic acid bacteria, bifidobacteria, etc. are vulnerable to acid, and even if live bacteria are ingested, most of them die due to gastric acid, bile acid, etc. Various methods such as selection and encapsulation of strains having sex have been performed.
[0006]
In addition, in order to improve the gut microbiota by increasing the number of bifidobacteria, etc. originally in the intestines, foods and drinks that contain various oligosaccharides (bifidobacterial growth factors) that are selectively assimilated by bifidobacteria There are some products, but if you take an amount of dietary fiber and the above oligosaccharides that can be expected to improve the gut microbiota, you may feel hungry or cause diarrhea.
[0007]
[Problems to be solved by the invention]
As described above, it is generally recognized that the balance improvement effect of intestinal flora by ingestion of lactic acid bacteria and bifidobacteria is derived from these live bacteria, and so far the death of lactic acid bacteria and bifidobacteria etc. There has been no study on the effect of improving the intestinal flora by cells. Moreover, when aiming at the improvement of intestinal microflora for the same reason, after adding lactic acid bacteria, bifidobacteria, etc., it is not performed adding to food-drinks that require heat treatment.
[0008]
Therefore, an object of the present invention is to provide an intestinal flora improving agent that has an excellent intestinal flora improving action and that does not impair the effect even by heat treatment, and a food and drink containing the same. It is in.
[0009]
[Means for Solving the Problems]
As a result of diligent research to achieve the above-mentioned object, the present inventors surprisingly ingested heat-treated cells such as lactic acid bacteria to promote the growth of bifidobacteria and suppress the growth of harmful bacteria. The present inventors have found that the gut microbiota is improved and have completed the present invention.
[0010]
That is, one of the present invention is an intestinal flora improving agent characterized by containing one or more heat-treated cells selected from lactic acid bacteria, bifidobacteria, natto and yeast as active ingredients.
[0011]
The intestinal flora improving agent of the present invention contains one or more kinds of heat-treated cells selected from lactic acid bacteria, bifidobacteria, natto and yeast as an active ingredient, but the reason is not clearly understood. It has the effect of promoting the growth of bifidobacteria in the intestine and suppressing the growth of harmful bacteria such as Clostridium perfringens to improve the intestinal flora to a good state. As a result, fecal properties can be improved and constipation symptoms can be improved. In addition, since the heat-treated cells such as lactic acid bacteria which are active ingredients are dead cells, the intestinal flora improving effect is not impaired even if the heat treatment is further performed. Therefore, it can be widely added to foods and drinks that require heat treatment, has high storage stability, and is extremely safe when used as a raw material for foods and drinks or pharmaceuticals.
[0012]
The intestinal flora improving agent of the present invention preferably contains a heat-treated bacterial body of lactic acid bacteria as an active ingredient. Moreover, it is preferable that the lactic acid bacterium is Enterococcus faecalis . According to these aspects, an intestinal flora improving agent having a higher intestinal flora improving effect can be obtained.
[0013]
Furthermore, it is preferable that the heat-treated cells are prepared so that 1 × 10 10 or more per day can be ingested. According to this aspect, an intestinal flora improving agent having a sufficient intestinal flora improving effect can be obtained.
[0014]
Moreover, another of this invention is the food / beverage products characterized by including the said intestinal microflora improving agent.
[0015]
Since the food / beverage products of this invention contain the intestinal microflora improving agent which contains heat-processed microbial cells, such as lactic acid bacteria, as an active ingredient, it can anticipate the intestinal microbiota improvement effect excellent in ingesting. Since the intestinal flora improving agent contains dead cells as an active ingredient, the effect of improving the intestinal flora is not impaired even in foods and drinks that require heat treatment, and unnecessary fermentation by lactic acid bacteria, etc. Does not occur, so it does not affect the storage stability of food and drink.
[0016]
DETAILED DESCRIPTION OF THE INVENTION
The intestinal flora improving agent of the present invention contains one or more types of heat-treated cells selected from lactic acid bacteria, bifidobacteria, natto bacteria and yeast as active ingredients.
[0017]
The lactic acid bacteria, for example, Enterococcus faecalis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, and the like Str eptococcus thermophilus.
Examples of Bifidobacterium include Bifidobacterium Longum , Bifidobacterium breve , Bifidobacterium bifidum, and the like.
Examples of Bacillus natto include Bacillus Natto .
Examples of yeast include Saccharomyces cerevisiae and Saccharomyces Carlsbergensis .
[0018]
The heat-treated microbial cell in the present invention is a dead microbial cell obtained by heat sterilizing the above bacterium, and from a culture obtained by culturing the above bacterium according to a conventional method, for example, filtration and centrifugation The bacterial cells can be collected by such a method, washed with water, suspended in water, etc., heat-treated at 80 to 115 ° C. for 30 minutes to 3 seconds, and then concentrated and dried as necessary.
[0019]
Intestinal flora improving agent of the present invention, the heating of preferably contains a heat treatment lactic acid bacteria among the bacteria, in particular Enterococcus faecalis (ATCC 19433, ATCC 14508 , ATCC 23655, IFO 16803, IFO 16804 , etc.) It is preferable to contain treated cells.
[0020]
The intestinal flora improving agent of the present invention can ingest 1 × 10 10 or more, more preferably 5 × 10 11 or more, particularly preferably 1 × 10 12 or more of the above-mentioned heat-treated cells of the bacterium per day. It is preferable to be prepared. If the daily intake of the heat-treated cells is less than the above, sufficient intestinal flora improvement effect cannot be expected.
[0021]
The intestinal flora-improving agent of the present invention, in addition to the above-mentioned heat-treated cells, added excipients, sweeteners, acidulants, vitamins, minerals, oligosaccharides, dietary fiber, etc. as necessary Then, it can be prepared as a powder, granule, tablet, capsule, pasty or jelly-like beverage.
[0022]
Further, the intestinal flora improving agent of the present invention includes, for example, various noodles such as bread, udon and ramen, various drinks such as natto, drinks and jelly drinks, jelly, gummy, candy, biscuits, instant soup and instant miso soup It can also be added to general foods and beverages such as various instant foods such as retort foods and foods compatible with microwave ovens. The amount of the intestinal flora-improving agent added to each food or drink is 1 × 10 10 or more, more preferably 5 × 10 11 or more, and particularly preferably 1 × 10 or more of the heat-treated cells in each food or drink. It is preferable to add 12 or more. In addition, there is no restriction | limiting in particular in the addition method, It can add from the beginning together with the other raw material used for each food-drinks.
[0023]
The intestinal flora-improving agent of the present invention contains heat-treated cells such as lactic acid bacteria, that is, dead cells, as an active ingredient, so that heat treatment (such as heat sterilization, baking, steaming, etc.) Even if it is added to foods and drinks that require the treatment below, the intestinal flora improving effect is not impaired.
[0024]
【Example】
Hereinafter, the present invention will be specifically described with reference to examples. In the following description, “%” represents “mass%” unless otherwise specified.
[0025]
Example
Enterococcus culture solution of Enterococcus faecalis (ATCC 19433) in Rogosa medium at 37 ° C. for 24 hours is inoculated to a liquid medium containing 4% yeast extract, 3% polypeptone and 10% lactose in 0.1 (v / v)%. Then, neutralization culture was performed at 37 ° C. for 22 to 24 hours while adjusting with a sodium hydroxide aqueous solution to pH 6.8 to 7.0 using a pH stat.
[0026]
After completion of the culture, the cells were separated and collected with a continuous centrifuge, then diluted with water to the original liquid volume, and again separated and collected with a continuous centrifuge. This operation was repeated a total of 4 times to wash the cells. Next, the washed cells were suspended in an appropriate amount of water, sterilized at 100 ° C. for 30 minutes, and then dried using a spray dryer to prepare a heat-treated cell powder.
[0027]
Test samples and placebos (each 1 g / pack) were prepared with the compositions shown in Table 1 using the obtained heat-treated cell powder, and experiments were conducted by the following methods. The test sample was prepared so as to contain 1 × 10 12 lactic acid bacteria heat-treated cells.
[0028]
[Table 1]
Figure 2004051530
[0029]
The experimental period is 4 weeks, and 8 volunteers are asked to take a placebo 1g / pack once a day for the first week before bedtime, and for the next 2 weeks, the test sample is taken in the same way. For the last week, they took a placebo as well. And day 0 (before the experiment), day 7 (1 week after taking the placebo), day 14 (1 week after taking the test sample), day 21 (2 weeks after taking the test sample), day 28 (placebo) The first week), each stool was collected, and changes in the flora in the stool were examined.
[0030]
The measurement of the flora in the stool was carried out according to the method of Mitsuoka Chitoshi (Infectious Diseases Journal, Vol. 45, No. 9, pp. 406-). That is, 1 g of collected feces was placed in a mortar, homogenized by adding 9 mL of an anaerobic diluent, and then diluted 10-fold using an anaerobic diluent. This diluted solution was applied to a BL medium and a neomycin Nagler agar medium (NN medium) and cultured at 37 ° C. under anaerobic conditions, and the total number of bacteria, Bacteroides, bifidobacteria and Welsh bacteria were measured. Incidentally, the anaerobic diluent, in distilled water, the KH 2 PO 4 4.5 g, the NaHPO 4 6.0 g, the L- cysteine hydrochloride 0.5g, the Tween 80 was added 0.5g, a total volume of 1000mL It was prepared. The total number of bacteria was determined by multiplying the number of colonies that appeared in the BL medium by the dilution factor. Bacteroides and Bifidobacteria were found by colonizing colonies that appeared in the BL medium and identified by Gram staining and microscopy. As the Clostridium perfringens, an NN medium was used, and those having a positive lecithinase reaction around the colonies were determined to be Clostridium perfringens. FIG. 1 shows changes in the total number of bacteria, the number of bifidobacteria, and the number of Clostridium perfringens contained in 1 g of stool.
[0031]
From FIG. 1, the number of bifidobacteria is significantly increased and the number of Welsh bacteria is significantly decreased in the experiment period 14 to 21 days corresponding to the administration period of the test sample (lactic acid bacteria heat-treated cells). I understand. The significant difference was tested by t-test.
[0032]
In addition, Table 2 shows the ratio of bifidobacteria and bacteroides to the total number of bacteria.
[0033]
[Table 2]
Figure 2004051530
[0034]
Similarly, it can be seen from Table 2 that the ratio of bifidobacteria in the total number of bacteria increased and the ratio of Bacteroides decreased in the experimental period from the 14th to the 21st days corresponding to the test sample dosing period. .
[0035]
Each subject was asked about the status of defecation during the experiment, and no symptoms such as diarrhea were observed. And in most subjects, including subjects who usually have constipation, during the experimental period corresponding to the period of taking the test sample, the number of defecations increased and fecal properties also improved, and constipation tended to improve.
[0036]
From the above results, ingestion of heat-treated cells of lactic acid bacteria ( Enterococcus fecalis ) promotes the growth of bifidobacteria in the intestines and suppresses the growth of harmful bacteria such as Bacteroides and Clostridium perfringens, and intestinal flora. It has been shown that there is an effect of improving constipation and also an effect of improving constipation.
[0037]
【The invention's effect】
As described above, according to the present invention, by containing one or more heat-treated cells selected from lactic acid bacteria, bifidobacteria, natto and yeast as active ingredients, the growth of bifidobacteria in the intestine can be increased. It is possible to provide an intestinal flora improving agent that has an effect of promoting and suppressing the growth of harmful bacteria such as Bacteroides and Clostridium perfringens. By ingesting this intestinal flora improving agent, the intestinal flora can be improved to a good state, and fecal properties can be improved to improve symptoms such as constipation.
[0038]
Since the intestinal flora improving agent of the present invention contains dead cells as an active ingredient, it can be widely added to foods and drinks that require heat treatment, and gives intestinal flora improving effects to various foods and drinks it can. Furthermore, even if added to foods and drinks, unnecessary fermentation by lactic acid bacteria does not occur, so it does not affect the storage stability of foods and drinks, and is safe when used as a raw material for foods and drinks and pharmaceuticals. The nature is also very high.
[Brief description of the drawings]
BRIEF DESCRIPTION OF DRAWINGS FIG. 1 is a diagram showing changes in stool flora due to ingestion of heat-treated cells of lactic acid bacteria ( Enterococcus fecalis ).

Claims (5)

乳酸菌、ビフィズス菌、納豆菌及び酵母から選ばれた1種以上の加熱処理菌体を有効成分として含有することを特徴とする腸内菌叢改善剤。An intestinal flora improving agent comprising as an active ingredient at least one heat-treated cell selected from lactic acid bacteria, bifidobacteria, natto bacteria, and yeast. 乳酸菌の加熱処理菌体を有効成分として含有する、請求項1に記載の腸内菌叢改善剤。The intestinal microflora improving agent of Claim 1 which contains the heat processing microbial cell of lactic acid bacteria as an active ingredient. 前記乳酸菌が乳酸球菌(Enterococcus faecalis)である、請求項1又は2に記載の腸内菌叢改善剤。The intestinal flora improving agent according to claim 1 or 2, wherein the lactic acid bacterium is Enterococcus faecalis . 前記加熱処理菌体を1日当たり1×1010個以上摂取できるように調製された、請求項1〜3のいずれか一つに記載の腸内菌叢改善剤。The intestinal flora improving agent according to any one of claims 1 to 3, which is prepared so that 1 x 10 10 or more of the heat-treated cells can be ingested per day. 請求項1〜4のいずれか一つに記載の腸内菌叢改善剤を含有することを特徴とする飲食品。Food / beverage products containing the intestinal microflora improving agent as described in any one of Claims 1-4.
JP2002210445A 2002-07-19 2002-07-19 Intestinal flora-improving agent and food or drink containing the same Pending JP2004051530A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002210445A JP2004051530A (en) 2002-07-19 2002-07-19 Intestinal flora-improving agent and food or drink containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002210445A JP2004051530A (en) 2002-07-19 2002-07-19 Intestinal flora-improving agent and food or drink containing the same

Publications (1)

Publication Number Publication Date
JP2004051530A true JP2004051530A (en) 2004-02-19

Family

ID=31933943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002210445A Pending JP2004051530A (en) 2002-07-19 2002-07-19 Intestinal flora-improving agent and food or drink containing the same

Country Status (1)

Country Link
JP (1) JP2004051530A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005247775A (en) * 2004-03-05 2005-09-15 Sankyo Seiyaku Kogyo Kk Nutrient composition for prevention and treatment
WO2005087241A1 (en) * 2004-03-16 2005-09-22 Combi Co. Infection-controlling agent for livestock, poultry or fish
WO2005087240A1 (en) * 2004-03-16 2005-09-22 Combi Co. Antidiarrheal agent for livestock and poultry
JP2006089421A (en) * 2004-09-24 2006-04-06 Combi Corp Agent for controlling infection caused by drug resistant bacterium
JP2008000121A (en) * 2006-06-20 2008-01-10 Bamen Kenichi Immunostimulating food, immunostimulating supplementary food, antitumor food, and antioxidative food
JP2008106064A (en) * 2006-09-28 2008-05-08 Honda Trading Corp T-pa accelerating material and its manufacturing method
JP2014054199A (en) * 2012-09-11 2014-03-27 Ito En Ltd Lactic acid bacteria-containing solid food product, production method thereof, and method for maintaining the number of bacteria contained in lactic acid bacteria-containing solid food product
CN105661239A (en) * 2016-03-02 2016-06-15 浙江大学 Mung bean and corn fermented juice and preparation method thereof
JP2019076089A (en) * 2017-10-23 2019-05-23 有限会社佐藤修商店 Fish meat paste and manufacturing method thereof
WO2019142793A1 (en) * 2018-01-17 2019-07-25 アサヒグループホールディングス株式会社 Packaged coffee beverage and method for improving quality of taste of packaged coffee beverage
WO2020166708A1 (en) * 2019-02-15 2020-08-20 コンビ株式会社 Novel lactic acid bacterium, and composition containing same
JP2021191740A (en) * 2020-06-05 2021-12-16 株式会社日本バリアフリー Intestinal flora improver containing lactic acid bacteria
CN113812622A (en) * 2021-09-10 2021-12-21 盛尚杞美(宁夏)生物科技开发有限公司 Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005247775A (en) * 2004-03-05 2005-09-15 Sankyo Seiyaku Kogyo Kk Nutrient composition for prevention and treatment
WO2005087241A1 (en) * 2004-03-16 2005-09-22 Combi Co. Infection-controlling agent for livestock, poultry or fish
WO2005087240A1 (en) * 2004-03-16 2005-09-22 Combi Co. Antidiarrheal agent for livestock and poultry
JPWO2005087241A1 (en) * 2004-03-16 2008-01-24 コンビ株式会社 Infection control agent for livestock, poultry or seafood
US7582305B2 (en) 2004-03-16 2009-09-01 Combi Co. Antidiarrheal agent for livestock and poultry
JP2006089421A (en) * 2004-09-24 2006-04-06 Combi Corp Agent for controlling infection caused by drug resistant bacterium
JP2008000121A (en) * 2006-06-20 2008-01-10 Bamen Kenichi Immunostimulating food, immunostimulating supplementary food, antitumor food, and antioxidative food
JP2008106064A (en) * 2006-09-28 2008-05-08 Honda Trading Corp T-pa accelerating material and its manufacturing method
JP2014054199A (en) * 2012-09-11 2014-03-27 Ito En Ltd Lactic acid bacteria-containing solid food product, production method thereof, and method for maintaining the number of bacteria contained in lactic acid bacteria-containing solid food product
CN105661239A (en) * 2016-03-02 2016-06-15 浙江大学 Mung bean and corn fermented juice and preparation method thereof
JP2019076089A (en) * 2017-10-23 2019-05-23 有限会社佐藤修商店 Fish meat paste and manufacturing method thereof
WO2019142793A1 (en) * 2018-01-17 2019-07-25 アサヒグループホールディングス株式会社 Packaged coffee beverage and method for improving quality of taste of packaged coffee beverage
JP2019122316A (en) * 2018-01-17 2019-07-25 アサヒ飲料株式会社 Container-packed coffee beverage and method for improving quality of taste of container-packed coffee beverage
JP7117853B2 (en) 2018-01-17 2022-08-15 アサヒ飲料株式会社 Packaged Coffee Beverage and Method for Improving Taste Quality of Packaged Coffee Beverage
WO2020166708A1 (en) * 2019-02-15 2020-08-20 コンビ株式会社 Novel lactic acid bacterium, and composition containing same
JP2021191740A (en) * 2020-06-05 2021-12-16 株式会社日本バリアフリー Intestinal flora improver containing lactic acid bacteria
CN113812622A (en) * 2021-09-10 2021-12-21 盛尚杞美(宁夏)生物科技开发有限公司 Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof

Similar Documents

Publication Publication Date Title
Saxelin et al. Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese
Leahy et al. Getting better with bifidobacteria
US8551473B2 (en) Metabolically active micro organisms and methods for their production
DK2478910T3 (en) ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE
TWI594758B (en) Composition comprising bifidobacteria,processes for the preparation thereof and uses thereof
US20100166721A1 (en) Probotic compositions and uses thereof
EP0555618B1 (en) Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria
US20110165127A1 (en) Dairy-derived probiotic compositions and uses thereof
HU228050B1 (en) Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain
JP2010521136A (en) Composition for improving intestinal flora
KR20050057259A (en) Probiotic bacterium : lactobacillus fermentum
KR20060135016A (en) Compostion comprising yucca extract, quillaia extract and lactic acid bacterium and food and drink containing the composition
JP2004051530A (en) Intestinal flora-improving agent and food or drink containing the same
CN113795155A (en) Probiotic bacterial strain producing short chain fatty acids and compositions comprising same
CN108882740A (en) Fermentating formula object containing indigestible oligosaccharides
CA2812909C (en) Compositions and methods for augmenting kidney function
RU2303058C2 (en) Agent &#34;biobalans-k&#34; for treatment of intestine infections complicated with dysbacteriosis
JP2018177703A (en) Toll-like receptor 2 activating composition
CN108697141A (en) Nutrient formulation object containing indigestible oligosaccharides and non-replicating lactic acid producing bacteria
JP4280016B2 (en) Diabetes complications prevention, improvement, treatment
Sip et al. Probiotics and prebiotics
Kumar et al. Bifidobacteria for life betterment
JP2006180836A (en) Lactic acid bacterium controlling infection with food poisoning bacterium, fermentation product, food and medicine composition containing the same
Marks Successful probiotic bifidobacteria
Kumari et al. Probiotics: from Science to Technology

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090721